EP1171078A4 - COMPOSITIONS AND METHODS ACTING ON THE CHOLESTEROL RATE OF HIGH DENSITY LIPOPROTEINS (HDL) AND APOLIPOPROTEINS AI, ON THE CHOLESTEROL RATES OF VERY LOW DENSITY LIPOPROTEINS (VLDL) AND ON THE CHOLESTEROL RATE OF LIPOPROTEINS (LDL) - Google Patents

COMPOSITIONS AND METHODS ACTING ON THE CHOLESTEROL RATE OF HIGH DENSITY LIPOPROTEINS (HDL) AND APOLIPOPROTEINS AI, ON THE CHOLESTEROL RATES OF VERY LOW DENSITY LIPOPROTEINS (VLDL) AND ON THE CHOLESTEROL RATE OF LIPOPROTEINS (LDL)

Info

Publication number: EP1171078A4
Authority: EP; European Patent Office
Prior art keywords: cholesterol; lipoproteins; rate; density lipoproteins; apolipoproteins
Prior art date: 1999-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP00918362A

Other languages

German (de)

French (fr)

Other versions

EP1171078A2 (en

Inventor

Michael Jaye

Kevin J Lynch

Dilip V Amin

Kim-Anh Thi Doan

Dawn Marchadier

Cyrille Maugeais

Daniel J Rader

John A Krawiec

Victoria J South

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharmaceuticals Inc

University of Pennsylvania Penn

Original Assignee

Aventis Pharmaceuticals Inc

University of Pennsylvania Penn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-26

Filing date

2000-03-24

Publication date

2002-11-06

1999-03-26 Priority claimed from US09/277,401 external-priority patent/US7008776B1/en

2000-03-24 Application filed by Aventis Pharmaceuticals Inc, University of Pennsylvania Penn filed Critical Aventis Pharmaceuticals Inc

2002-01-16 Publication of EP1171078A2 publication Critical patent/EP1171078A2/en

2002-11-06 Publication of EP1171078A4 publication Critical patent/EP1171078A4/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Microbiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Investigating Or Analysing Biological Materials (AREA)

EP00918362A 1999-03-26 2000-03-24 COMPOSITIONS AND METHODS ACTING ON THE CHOLESTEROL RATE OF HIGH DENSITY LIPOPROTEINS (HDL) AND APOLIPOPROTEINS AI, ON THE CHOLESTEROL RATES OF VERY LOW DENSITY LIPOPROTEINS (VLDL) AND ON THE CHOLESTEROL RATE OF LIPOPROTEINS (LDL) Ceased EP1171078A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/277,401 US7008776B1 (en)	1996-12-06	1999-03-26	Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US277401		1999-03-26
PCT/US2000/007870 WO2000057837A2 (en)	1999-03-26	2000-03-24	Compositions and methods for effecting the levels of cholesterol

Publications (2)

Publication Number	Publication Date
EP1171078A2 EP1171078A2 (en)	2002-01-16
EP1171078A4 true EP1171078A4 (en)	2002-11-06

Family

ID=23060703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00918362A Ceased EP1171078A4 (en)	1999-03-26	2000-03-24	COMPOSITIONS AND METHODS ACTING ON THE CHOLESTEROL RATE OF HIGH DENSITY LIPOPROTEINS (HDL) AND APOLIPOPROTEINS AI, ON THE CHOLESTEROL RATES OF VERY LOW DENSITY LIPOPROTEINS (VLDL) AND ON THE CHOLESTEROL RATE OF LIPOPROTEINS (LDL)

Country Status (13)

Country	Link
EP (1)	EP1171078A4 (en)
JP (1)	JP2002540127A (en)
KR (2)	KR20050044812A (en)
AU (1)	AU776684B2 (en)
BR (1)	BR0009333A (en)
CA (1)	CA2363486C (en)
HK (1)	HK1043309A1 (en)
IL (2)	IL145526A0 (en)
MX (1)	MXPA01009727A (en)
NO (2)	NO331779B1 (en)
NZ (2)	NZ531180A (en)
WO (1)	WO2000057837A2 (en)
ZA (1)	ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7507808B2 (en) *	2002-12-12	2009-03-24	Isis Pharmaceuticals, Inc.	Modulation of endothelial lipase expression
CN101437933B (en)	2005-12-28	2013-11-06	斯克里普斯研究所	Natural antisense and non-coding RNA transcripts as drug targets
ES2600781T3 (en)	2008-12-04	2017-02-10	Curna, Inc.	Treatment for diseases related to vascular endothelial growth factor (vegf) by inhibiting natural antisense transcripts of vegf
US8921329B2 (en)	2008-12-04	2014-12-30	Curna, Inc.	Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
EP2370582B1 (en)	2008-12-04	2017-05-10	CuRNA, Inc.	Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CA2752237C (en)	2009-02-12	2020-03-24	Opko Curna, Llc	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
ES2656290T3 (en)	2009-03-16	2018-02-26	Curna, Inc.	Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2
WO2010107740A2 (en)	2009-03-17	2010-09-23	Curna, Inc.	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
KR101835889B1 (en)	2009-05-06	2018-03-08	큐알엔에이, 인크.	Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
WO2010129746A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
KR101742334B1 (en)	2009-05-08	2017-06-01	큐알엔에이, 인크.	Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
NO2432881T3 (en)	2009-05-18	2018-04-14
KR101703695B1 (en)	2009-05-22	2017-02-08	큐알엔에이, 인크.	Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
US8791085B2 (en)	2009-05-28	2014-07-29	Curna, Inc.	Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
EP2443237B1 (en)	2009-06-16	2017-02-22	CuRNA, Inc.	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
JP6128846B2 (en)	2009-06-16	2017-05-17	クルナ・インコーポレーテッド	Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1)
WO2010151671A2 (en)	2009-06-24	2010-12-29	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CN102482672B (en)	2009-06-26	2016-11-09	库尔纳公司	By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene
JP2013500017A (en)	2009-07-24	2013-01-07	カッパーアールエヌエー，インコーポレイテッド	Treatment of sirtuin (SIRT) related diseases by blocking natural antisense transcripts to sirtuin (SIRT)
CN102762731B (en)	2009-08-05	2018-06-22	库尔纳公司	By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
WO2011019815A2 (en)	2009-08-11	2011-02-17	Curna, Inc.	Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8791087B2 (en)	2009-08-21	2014-07-29	Curna, Inc.	Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
US9023822B2 (en)	2009-08-25	2015-05-05	Curna, Inc.	Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
US20120295952A1 (en)	2009-09-25	2012-11-22	Curna, Inc.	Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
JP6025567B2 (en)	2009-12-16	2016-11-16	カッパーアールエヌエー，インコーポレイテッド	Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1)
CN102781480B (en)	2009-12-23	2018-07-27	库尔纳公司	UCP2 relevant diseases are treated by inhibiting the natural antisense transcript of uncoupling protein-3 (UCP2)
KR101891352B1 (en)	2009-12-23	2018-08-24	큐알엔에이, 인크.	Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
EP2519633B1 (en)	2009-12-29	2017-10-25	CuRNA, Inc.	Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
CN102770540B (en)	2009-12-29	2017-06-23	库尔纳公司	P63 relevant diseases are treated by suppressing the natural antisense transcript of oncoprotein 63 (p63)
WO2011082281A2 (en)	2009-12-31	2011-07-07	Curna, Inc.	Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
CA2785832A1 (en)	2010-01-04	2011-07-07	Curna, Inc.	Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
JP5963680B2 (en)	2010-01-06	2016-08-03	カッパーアールエヌエー，インコーポレイテッド	Treatment of pancreatic developmental gene diseases by inhibition of natural antisense transcripts against pancreatic developmental genes
CN102803493B (en)	2010-01-11	2018-07-31	库尔纳公司	SHBG relevant diseases are treated by inhibiting the natural antisense transcript of sex hormone binding globulin (SHBG)
CN102782135A (en)	2010-01-25	2012-11-14	库尔纳公司	Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
RU2608496C2 (en)	2010-02-22	2017-01-18	Курна, Инк.	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
US8980856B2 (en)	2010-04-02	2015-03-17	Curna, Inc.	Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
JP5978203B2 (en)	2010-04-09	2016-08-24	カッパーアールエヌエー，インコーポレイテッド	Treatment of fibroblast growth factor (FGF21) fibroblast growth factor FGF21) related diseases by inhibition of natural antisense transcripts against FGF21
KR101992076B1 (en)	2010-05-03	2019-06-21	큐알엔에이, 인크.	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (en)	2010-05-14	2016-05-01	可娜公司	Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
KR101902197B1 (en)	2010-05-26	2018-10-01	큐알엔에이, 인크.	Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
KR20180053419A (en)	2010-05-26	2018-05-21	큐알엔에이, 인크.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
CA2803882C (en)	2010-06-23	2022-10-18	Opko Curna, Llc	Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EP2593547B1 (en)	2010-07-14	2017-11-15	CuRNA, Inc.	Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
RU2624048C2 (en)	2010-10-06	2017-06-30	Курна, Инк.	Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition
RU2597972C2 (en)	2010-10-22	2016-09-20	Курна Инк.	Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en)	2010-11-18	2012-05-24	Opko Curna Llc	Antagonat compositions and methods of use
JP6071893B2 (en)	2010-11-23	2017-02-01	カッパーアールエヌエー，インコーポレイテッド	Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG
EP2718439B1 (en)	2011-06-09	2017-08-09	CuRNA, Inc.	Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
EP2753317B1 (en)	2011-09-06	2020-02-26	CuRNA, Inc.	TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
PT2825648T (en)	2012-03-15	2018-11-09	Scripps Research Inst	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
CN102628060A (en) *	2012-03-22	2012-08-08	北京济福霖生物技术有限公司	Production method of low-fat milk
EP2915882B1 (en) *	2012-11-05	2018-10-17	Shionogi & Co., Ltd.	Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
SG10201707233UA (en)	2013-03-14	2017-10-30	Shionogi & Co	Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
TWI688575B (en)	2014-09-11	2020-03-21	日商塩野義製藥股份有限公司	Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
WO2022165313A1 (en)	2021-02-01	2022-08-04	Regenxbio Inc.	Gene therapy for neuronal ceroid lipofuscinoses
US20240277861A1 (en) *	2021-07-26	2024-08-22	Purotech Bio, Inc.	Anti-hepatitis b virus agent targeting host factor lipg

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024888A2 (en) *	1996-12-06	1998-06-11	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) *	1997-12-19	1999-07-01	Progenitor, Inc.	A lipase expressed in endothelial cells and methods for its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994013791A1 (en) *	1992-12-04	1994-06-23	Innovir Laboratories, Inc.	Regulatable nucleic acid therapeutic and methods of use thereof

2000
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/en not_active Application Discontinuation
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 IL IL14552600A patent/IL145526A0/en unknown
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/en active IP Right Grant
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/en active Pending
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/en active Search and Examination
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/en not_active IP Right Cessation
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/en not_active IP Right Cessation
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/en unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/en not_active IP Right Cessation
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/en unknown
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/en not_active IP Right Cessation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998024888A2 (en) *	1996-12-06	1998-06-11	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Polypeptides encoded by a human lipase-like gene, compositions and methods
WO1999032611A1 (en) *	1997-12-19	1999-07-01	Progenitor, Inc.	A lipase expressed in endothelial cells and methods for its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRATA KEN-ICHI ET AL: "Cloning of a unique lipase from endothelial cells extends the lipase gene family", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 20, 14 May 1999 (1999-05-14), pages 14170 - 14175, XP002195654, ISSN: 0021-9258 *

Also Published As

Publication number	Publication date
NO331784B1 (en)	2012-03-26
WO2000057837A8 (en)	2001-09-27
NO20014657D0 (en)	2001-09-25
HK1043309A1 (en)	2002-09-13
KR20020029651A (en)	2002-04-19
EP1171078A2 (en)	2002-01-16
BR0009333A (en)	2002-01-08
WO2000057837A9 (en)	2001-10-18
NO20100214L (en)	2001-11-21
IL145526A0 (en)	2002-06-30
CA2363486A1 (en)	2000-10-05
NZ531180A (en)	2005-06-24
WO2000057837A2 (en)	2000-10-05
NZ514350A (en)	2004-12-24
AU3918700A (en)	2000-10-16
KR100887164B1 (en)	2009-03-10
IL145526A (en)	2010-11-30
WO2000057837A3 (en)	2001-01-25
ZA200107598B (en)	2003-05-28
NO20014657L (en)	2001-11-21
NO331779B1 (en)	2012-03-26
JP2002540127A (en)	2002-11-26
AU776684B2 (en)	2004-09-16
MXPA01009727A (en)	2002-07-22
KR20050044812A (en)	2005-05-12
CA2363486C (en)	2012-12-18

Publication	Publication Date	Title
EP1171078A4 (en)	2002-11-06	COMPOSITIONS AND METHODS ACTING ON THE CHOLESTEROL RATE OF HIGH DENSITY LIPOPROTEINS (HDL) AND APOLIPOPROTEINS AI, ON THE CHOLESTEROL RATES OF VERY LOW DENSITY LIPOPROTEINS (VLDL) AND ON THE CHOLESTEROL RATE OF LIPOPROTEINS (LDL)
EE200300136A (en)	2003-08-15	Compositions and methods for lowering plasma lipoprotein (a) levels and reducing risk factors for cardiovascular disease
HK1049723A1 (en)	2003-05-23	Method and apparatus for internet, intranet, and local viewing of virtual microscope slides
GB0114989D0 (en)	2001-08-08	Web server apparatus for virus checking
IL179019A0 (en)	2007-03-08	Method and apparatus for the dynamic filtering and routing of events
HK1068569A1 (en)	2005-04-29	Apparatus and method for rapid disruption of cellsor viruses
DE69909263D1 (en)	2003-08-07	CONTINUOUS REMOVAL OF VOLATILE COMPONENTS FROM SUSPENSION POLYMERISATION
AU4307799A (en)	1999-11-29	Apparatus and method for confinement and damping of vibration energy
AU2002330154A1 (en)	2003-04-07	Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AP2006003817A0 (en)	2006-12-31	methods and compositions for treating hepatitis C virus
AU2002230042A1 (en)	2002-10-28	Method and apparatus for efficient routing of mobile node packets
AU2001251376A1 (en)	2001-11-12	Stability enhanced water-in-oil emulsion and method for using same
HU0100388D0 (en)	2001-03-28	Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterol
AU4228600A (en)	2000-11-14	Compositions and methods for removing pollutants from contaminated materials
DK1383733T3 (en)	2008-06-09	Process for Preparation of 1,3-Substituted Domains and Aryl-Joined Azapolycyclic Compounds
AU6927400A (en)	2001-03-19	Method and apparatus for improving stability of moving webs
AU2001252276A1 (en)	2001-11-20	Method for reducing the spread of computer viruses in an electronic mail network
AU4985899A (en)	2000-02-01	Method of removing carbon from fly ash
AU2001289842A1 (en)	2002-04-08	Method and apparatus for managing traffic flows
AU2002326788A1 (en)	2003-03-18	Method for discovering new infectious particles
AU2002221657A1 (en)	2002-05-06	Method and system for preventing the spread of computer viruses
AU3065999A (en)	1999-09-27	Compositions and methods for treatment of asthma
AU1924301A (en)	2001-06-04	Method for operating an integrated point of presence server network
DK0885208T3 (en)	2001-10-15	Taxoids, preparation of these compounds and pharmaceutical compositions containing these compounds
AU2002217033A1 (en)	2003-06-10	Method for developing and managing large-scale web user interfaces

Legal Events

Date	Code	Title	Description
2001-11-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2002-01-16	17P	Request for examination filed	Effective date: 20011017
2002-01-16	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-01-16	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2002-11-06	A4	Supplementary search report drawn up and despatched	Effective date: 20020925
2002-11-06	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-11-06	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 6/00 A, 7C 12N 9/20 B
2002-11-20	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AVENTIS PHARMACEUTICALS PRODUCTS INC. Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
2004-11-03	17Q	First examination report despatched	Effective date: 20040915
2006-02-08	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Owner name: AVENTIS PHARMACEUTICALS INC.
2006-09-13	RIN1	Information on inventor provided before grant (corrected)	Inventor name: KRAWIEC, JOHN, A. Inventor name: MARCHADIER, DAWN Inventor name: MAUGEAIS, CYRILLE Inventor name: RADER, DANIEL, J. Inventor name: JAYE, MICHAEL Inventor name: SOUTH, VICTORIA, J. Inventor name: LYNCH, KEVIN, J. Inventor name: AMIN, DILIP, V. Inventor name: DOAN, KIM-ANH, THI
2006-11-02	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AVENTIS PHARMACEUTICALS, INC. Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
2007-01-10	RIN1	Information on inventor provided before grant (corrected)	Inventor name: LYNCH, KEVIN, J. Inventor name: RADER, DANIEL, J. Inventor name: KRAWIEC, JOHN, A. Inventor name: DOAN, KIM-ANH, THI Inventor name: MAUGEAIS, CYRILLE Inventor name: MARCHADIER, DAWN Inventor name: AMIN, DILIP, V. Inventor name: JAYE, MICHAEL Inventor name: SOUTH, VICTORIA, J.
2008-07-16	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AVENTIS PHARMACEUTICALS INC. Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
2009-01-31	APBK	Appeal reference recorded	Free format text: ORIGINAL CODE: EPIDOSNREFNE
2009-01-31	APBN	Date of receipt of notice of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA2E
2009-04-03	APBR	Date of receipt of statement of grounds of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA3E
2009-04-22	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2012-03-02	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2013-09-06	REG	Reference to a national code	Ref country code: DE Ref legal event code: R003
2013-09-25	APBT	Appeal procedure closed	Free format text: ORIGINAL CODE: EPIDOSNNOA9E
2013-11-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2013-12-11	18R	Application refused	Effective date: 20130906
2014-10-17	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1043309 Country of ref document: HK